Je selectiemandje is leeg.
Maak een selectie van ETF's die je wilt vergelijken.
Voeg een ETF toe door op "Vergelijk" te klikken op een ETF-profiel of door een ETF aan te vinken in de ETF-zoekfunctie.
Jazz Pharmaceuticals
ISIN IE00B4Q5ZN47
|WKN A1JS1K
Marktkapitalisatie (in EUR)
9.869 m
Land
Ierland
Sector
Gezondheidszorg
Dividendrendement
0,00%
Overzicht
Koers
Beschrijving
Jazz Pharmaceuticals Plc is een biofarmaceutisch bedrijf dat zich richt op de identificatie, ontwikkeling en commercialisering van farmaceutische producten op het gebied van narcolepsie, oncologie, pijn en psychiatrie. De productportefeuille omvat: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos en Defitelio. Het bedrijf werd in maart 2003 opgericht door Bruce C. Cozadd en het hoofdkantoor is gevestigd in Dublin, Ierland.
Gezondheidszorg Biofarmaceutica Systeemspecifieke Biofarmaceutica Ierland
Grafiek
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 9.869 m |
| WPA, EUR | -5,29 |
| KBV | 2,6 |
| K/W | 15,7 |
| Dividendrendement | 0,00% |
Winst- en verliesrekening (2025)
| Omzet, EUR | 3.783 m |
| Netto-inkomen, EUR | -316 m |
| Winstmarge | -8,35% |
In welke ETF zit Jazz Pharmaceuticals?
Er zijn 12 ETF's die Jazz Pharmaceuticals bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van Jazz Pharmaceuticals is de iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Prestaties
Rendementsoverzicht
| YTD | +8,30% |
| 1 maand | +11,61% |
| 3 maanden | +9,57% |
| 6 maanden | +45,41% |
| 1 jaar | +24,81% |
| 3 jaar | +24,91% |
| 5 jaar | +11,69% |
| Since inception | +59,55% |
| 2025 | +23,85% |
| 2024 | +4,51% |
| 2023 | -24,44% |
| 2022 | +27,06% |
Maandelijks rendement in een heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 42.00% |
| Volatility 3 years | 32.71% |
| Volatility 5 years | 30.90% |
| Return per risk 1 year | 0.59 |
| Return per risk 3 years | 0.23 |
| Return per risk 5 years | 0.07 |
| Maximum drawdown 1 year | -33.87% |
| Maximum drawdown 3 years | -37.14% |
| Maximum drawdown 5 years | -46.60% |
| Maximum drawdown since inception | -46.60% |
Rolling 1 year volatility
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.